The nomination committee proposes that the board of directors shall consist of existing and two new board members. The nomination committee unanimously recommends the election of the following new directors to the Board: Torill Standal Eliassen and Christopher Baldegger.
Mrs. Torill Standal Eliassen is a Norwegian citizen. She currently holds the position as Sales and Marketing Director in Avento AS. Previously she has held several positions in GE Healthcare in Norway and France. Mrs. Eliassen holds a diploma in international marketing and exports from NMH and ESC in Nantes and Grenoble.
Mr. Christoper Baldegger a Swiss citizen. He is the founder and partner in the Swiss seafood fund, Bonafide Ltd. During the last couple of months, Bonafide Ltd. has acquired substantial share holdings in Hofseth BioCare ASA and have signed up in the recent bond issue from HBC.
Proposed resolution:
The Board of Directors in Hofseth BioCare ASA shall consist of the following members:
Kjetil Olsen, Chairman
Henriette Godø Heggdal, Board Member
Marit Liland Sandvold, Board Member
Roger Hofseth, Board Member
Bjørn Petter Tunheim, Board Member
Torill Standal Eliassen, Board Member
Christopher Baldegger, Board Member
Ola Holen, Deputy Board Member
For further information, please contact:
Øystein Omvik, CFO Hofseth BioCare ASA
Tel: +47 936 99 400
E-mail: oystein.omvik@hofsethbiocare.no
About Hofseth BioCare:
Hofseth BioCare is a Norwegian biotech company that offers high-value ingredients and finished products for humans and pets. The company is founded on the core values of sustainability, traceability and optimal utilization of natural resources. Through an innovative hydrolysis technology, Hofseth BioCare is able to preserve the quality of salmon oil, proteins and calcium, prepared of fresh salmon off-cuts. HBCs objective is to contribute to the efficient use of marine resources and deliver quality products for ingredients and finished consumer products in the nutrition market.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.